Bristol Myers' schizophrenia drug reduces symptoms without weight gain in late-stage studies

Bristol Myers Squibb said on Saturday data from late-stage studies of its experimental schizophrenia drug showed it helped reduce symptoms of the disorder without the common side effect of weight gain tied to other antipsychotics. The drugmaker gained access to the treatment, called KarXT, through its $14 billion deal to buy Karuna Therapeutics last year. "Current antipsychotic treatments are associated with a number of adverse effects, including adverse metabolic profiles, increases in weight ... and there still remains a need for more effective treatments," said Roland Chen, SVP, global drug development for immunology, neuroscience and cardiovascular development at Bristol Myers.

Related Keywords

Bengaluru , Karnataka , India , Bristol Myer , Shilpi Majumdar , Roland Chen , Bristol Myers , Bristol Myers Squibb , Reuters , Myers Squibb , Karuna Therapeutics , Antipsychotics ,